Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Time critical stabilization
Airway compromise
Altered mental status with loss of protective reflexes
Severe sepsis with impending respiratory failure
Shock physiology
MAP target 65 mm Hg
Lactate trending for perfusion
Sepsis bundle triggers
Suspected infection with hypotension after fluids
Lactate 4 mmol/L or higher
Limb threat triggers
Acute compartment syndrome concern
Critical limb ischemia concern
Spine threat triggers
New focal weakness
Bowel or bladder dysfunction
Early consultation and activation
Orthopedics consultation triggers
Suspected acute hematogenous osteomyelitis with abscess
Failure of outpatient therapy
Neurosurgery consultation triggers
Suspected vertebral osteomyelitis with neurologic deficit
Suspected spinal epidural abscess
Infectious diseases consultation triggers
Bacteremia
Prosthetic material involvement
Vascular surgery consultation triggers
Diabetic foot infection with ischemia
Suspected necrotizing infection
Antibiotics timing decision
Culture before antibiotics pathway
Hemodynamic stability
No neurologic compromise
Planned image guided bone biopsy within 24 to 48 hours
Immediate antibiotics pathway
Sepsis or septic shock
Rapidly progressive soft tissue infection
Neurologic deficit
Initial diagnostics bundle
Blood cultures
Two sets before antibiotics when feasible
Repeat cultures for persistent bacteremia concern
Baseline inflammatory markers
CRP for trend
ESR for supportive evidence
Early imaging pathway selection
Radiographs for baseline and alternate diagnoses
MRI for extent and abscess
Key concepts
Conceptual framework
Infection pathways
Hematogenous seeding
Contiguous spread from soft tissue
Direct inoculation from trauma or surgery
High risk phenotypes
Vertebral osteomyelitis
Diabetic foot osteomyelitis
Core management pillars
Microbiologic diagnosis
Source control
Prolonged targeted antimicrobial therapy
PITFALLS
Common errors
Normal early radiograph interpreted as exclusion
Radiographic changes often delayed 10 to 14 days
MRI preferred for early disease
Antibiotics started before cultures in stable patient
Reduced culture yield from bone biopsy
Prefer cultures first when safe
Vertebral infection missed as mechanical back pain
Fever often absent
Elevated ESR or CRP supports infection
Diabetic foot osteomyelitis missed
Neuropathy masking pain
Probe to bone positive increases likelihood
History
Presentation patterns
Symptom pattern and timeline
Pain
Localized deep pain
Pain with weight bearing
Systemic symptoms
Fever
Rigors
Functional limitation
Limp
Reduced range of motion near involved bone
Vertebral pattern
Back pain
Night pain
Radicular symptoms
Diabetic foot pattern
Chronic ulcer duration
Worsening drainage or odor
Risk factors and exposures
Risk assessment
Bacteremia sources
Skin and soft tissue infection
Endocarditis risk factors
Immunocompromise
Diabetes mellitus
Chronic kidney disease
Neutropenia
Chronic corticosteroid therapy
Vascular compromise
Peripheral arterial disease
Smoking
Direct inoculation
Open fracture
Recent orthopedic surgery
IVDU
Pseudomonas risk
MRSA risk
Aquatic exposure
Brackish water exposure
Freshwater exposure
Microbiology clues
Organism risk clues
MRSA risk
Prior MRSA colonization or infection
Recent hospitalization
Gram negative risk
Recent urinary tract infection
IVDU
Anaerobe risk
Chronic ischemic ulcer
Foul smelling wound
Physical Exam
General and systemic
Systemic findings
Vital signs
Fever
Tachycardia
Sepsis features
Hypotension
Altered mental status
Endocarditis stigmata
New murmur
Peripheral embolic signs
Local exam by site
Local findings
Bone and joint region
Focal tenderness
Pain with motion near adjacent joint
Soft tissue
Erythema
Fluctuance suggesting abscess
Wound evaluation
Drainage
Sinus tract
Diabetic foot focused exam
Ulcer assessment
Ulcer depth
Visible bone or tendon
Probe to bone test
Positive contact with hard gritty surface
Higher likelihood of osteomyelitis when ulcer present
Perfusion assessment
Capillary refill
Dorsalis pedis and posterior tibial pulses
Spine and neurologic exam
Spine tenderness
Midline vertebral tenderness
Pain with percussion
Neurologic deficits
Motor weakness
Sensory level
Saddle anesthesia
PITFALLS
Misleading findings
Afebrile presentation
Common in vertebral osteomyelitis
Common in older adults
Minimal overlying skin changes
Possible in hematogenous osteomyelitis
Possible in early disease
Differential Diagnosis
Life threatening and limb threatening
Critical differentials
Septic arthritis ICD-10 M00
Painful limited joint range of motion
Effusion and warmth
Necrotizing soft tissue infection ICD-10 M72.6
Pain out of proportion
Rapid progression
Spinal epidural abscess ICD-10 G06.1
Back pain
Neurologic deficit
Acute limb ischemia ICD-10 I74
Pulselessness
Cool mottled extremity
Mimics and related conditions
Common mimics
Cellulitis ICD-10 L03
Superficial erythema
No focal bony tenderness
Gout ICD-10 M10
Acute episodic course
Hyperuricemia may be absent
Charcot neuroarthropathy ICD-10 M14.6
Warm swollen foot
Minimal pain with neuropathy
Fracture ICD-10 S82 and site specific
Trauma history
Point tenderness
Malignancy ICD-10 C40 to C41
Night pain
Weight loss
Laboratory Tests
Core labs
Baseline inflammatory and organ function
Complete blood count for leukocytosis and anemia
Normal WBC does not exclude osteomyelitis
Leukocytosis more common in acute disease
CRP for diagnosis support and response tracking
More responsive to treatment than ESR
Decline supports clinical improvement
ESR for diagnosis support
Often elevated in vertebral osteomyelitis
Slow to normalize
Basic metabolic panel for renal dosing
Creatinine trend for nephrotoxic antibiotics
Potassium for TMP-SMX risk
Liver enzymes for medication selection
Rifampin hepatotoxicity risk
Linezolid alternative considerations
Microbiology
Cultures and pathogen identification
Blood cultures for hematogenous source
Highest yield in acute hematogenous osteomyelitis
Persistent positivity suggests endovascular focus
Bone biopsy culture for definitive microbiology
Image guided biopsy for vertebral osteomyelitis
Hold antibiotics if stable to improve yield
Deep tissue culture from debridement
Preferred over superficial swab
Polymicrobial patterns common in diabetic foot
Additional tests by context
Targeted labs
Lactate for sepsis severity
Elevated lactate supports hypoperfusion
Trend for resuscitation response
Hemoglobin A1c for diabetes control planning
Poor control increases infection risk
Impacts wound healing
Creatine kinase for daptomycin safety baseline
Myopathy monitoring
Weekly monitoring during therapy
Diagnostic Tests
Scoring Systems
Risk and severity frameworks
Sepsis screening tools
qSOFA components
RR 22 per minute or higher
SBP 100 mm Hg or lower
Altered mentation
SOFA trend for organ dysfunction
Rising score supports ICU consideration
Lactate and vasopressor need integration
Diabetic foot infection severity grading
Mild infection
Local infection limited to skin and subcutaneous tissue
Erythema 2 cm or less around wound
Moderate infection
Deeper involvement
Erythema greater than 2 cm
Severe infection
Systemic inflammatory response
Hemodynamic instability
Probe to bone test interpretation
Positive test increases likelihood in diabetic foot ulcer
Best performance in high pretest probability ulcers
Negative test lowers likelihood in low risk ulcers
MRI
MRI strategy
Indications
Suspected early osteomyelitis with nondiagnostic radiograph
Suspected abscess or sinus tract
Diagnostic performance
High sensitivity for marrow edema
Specificity reduced by recent surgery and Charcot changes
Protocol considerations
Contrast for abscess delineation when renal function allows
Whole region imaging for skip lesions
Interpretation pearls
Marrow edema and enhancement pattern
Cortical disruption and sinus tract support diagnosis
CT
CT role
Indications
Cortical bone detail for chronic osteomyelitis
Surgical planning for sequestrum and involucrum
Limitations
Lower sensitivity for early marrow changes
Metal artifact with hardware
Technique pearls
Contrast for soft tissue abscess when MRI unavailable
Dual energy and metal artifact reduction when available
Ultrasound
Ultrasound applications
Soft tissue and fluid assessment
Subperiosteal fluid collection in children
Adjacent abscess localization for drainage
Guidance
Aspiration of superficial collections
Vascular access for prolonged therapy
Limitations
Limited evaluation of marrow
Cannot exclude osteomyelitis when negative
Disposition
Admission and level of care
Disposition decision
ICU indications
Septic shock
Rapidly progressive infection with organ dysfunction
Inpatient admission indications
Bacteremia
Vertebral osteomyelitis
Uncontrolled pain
Need for IV antibiotics with monitoring
Need for operative debridement
Transfer indications
Need for subspecialty surgery not available
Spinal cord compression concern
Outpatient management criteria
Hemodynamic stability
No neurologic deficits
Reliable follow up within 48 to 72 hours
Clear outpatient antibiotic plan and monitoring
Follow up and monitoring
Post disposition plan
Infectious diseases follow up
Antibiotic selection and duration
Lab monitoring schedule
Orthopedics or podiatry follow up
Wound care plan
Offloading and immobilization plan
Red flag return plan
Worsening pain or swelling
Fever recurrence
Treatment
Source control and supportive care
Non antimicrobial management
Source control
Abscess drainage
Percutaneous drainage when feasible
Operative drainage for deep or loculated collections
Debridement
Removal of necrotic bone
Removal of foreign material when possible
Amputation considerations
Non salvageable limb
Extensive necrosis with ischemia
Immobilization and offloading
Splinting for pain control
Reduced mechanical stress
Improved comfort
Diabetic foot offloading
Total contact cast option
Removable boot option
Empiric antibiotics
Empiric therapy framework
Timing
If stable and biopsy planned then hold antibiotics
If sepsis or neurologic deficit then initiate immediately
Coverage targets
Staphylococcus aureus including MRSA
Streptococci
Gram negative bacilli when risk factors present
Adult empiric regimens
Vancomycin IV
Loading dose 20 to 25 mg per kg actual body weight for severe infection
Maintenance 15 to 20 mg per kg IV every 8 to 12 hours
AUC to MIC target 400 to 600
If trough based monitoring then target trough 15 to 20 mg per L
Cefepime IV for gram negative risk
2 g IV every 8 to 12 hours
Renal dose adjustment required
Neurotoxicity risk with renal impairment
Piperacillin tazobactam IV for polymicrobial diabetic foot
4.5 g IV every 6 hours
Renal dose adjustment required
Enhanced nephrotoxicity risk with vancomycin
Meropenem IV for ESBL risk
1 g IV every 8 hours
Seizure risk in renal impairment
Reserve for high risk settings
Targeted antibiotics by organism
Pathogen directed therapy
MSSA
Cefazolin IV
2 g IV every 8 hours
Renal dose adjustment required
Preferred for many non CNS infections
Nafcillin IV
2 g IV every 4 hours
Hepatotoxicity and neutropenia monitoring
Sodium load consideration
MRSA
Vancomycin IV
AUC to MIC target 400 to 600
Nephrotoxicity monitoring
Infusion reaction prevention with slower rate
Daptomycin IV
6 to 8 mg per kg IV once daily
CK monitoring weekly
Not for pneumonia
Linezolid PO or IV
600 mg every 12 hours
Thrombocytopenia risk with prolonged use
Serotonin syndrome risk with serotonergic drugs
Streptococci
Penicillin G IV
4 million units IV every 4 hours
Adjust for renal dysfunction
Narrow spectrum option when susceptible
Ceftriaxone IV
2 g IV once daily
Good bone penetration
Biliary sludging risk
Enterobacterales
Ceftriaxone IV when susceptible
2 g IV once daily
Not for suspected AmpC high risk organisms
Step down to oral based on susceptibility and stability
Ciprofloxacin PO or IV when susceptible
400 mg IV every 12 hours
750 mg PO every 12 hours
Tendinopathy and QT risk
Pseudomonas aeruginosa
Cefepime IV
2 g IV every 8 hours
Consider extended infusion strategy
Renal dose adjustment required
Piperacillin tazobactam IV
4.5 g IV every 6 hours
Consider extended infusion strategy
Renal dose adjustment required
Anaerobes
Metronidazole PO or IV
500 mg every 8 hours
Neuropathy risk with prolonged use
Alcohol interaction
Clindamycin PO or IV when susceptible
600 to 900 mg IV every 8 hours
300 to 450 mg PO every 6 to 8 hours
C difficile infection risk
Duration and route
Treatment course planning
Typical duration targets
Acute hematogenous osteomyelitis adults
6 weeks typical duration
Longer duration for slow response or extensive disease
Vertebral osteomyelitis
6 weeks typical duration
Extend for epidural abscess or persistent bacteremia
Diabetic foot osteomyelitis
6 weeks when bone retained
Shorter course after complete resection with clean margins
IV to oral transition criteria
Hemodynamic stability
Downtrending CRP
Known susceptible organism
High bioavailability oral option available
Oral options with good bioavailability
Linezolid
600 mg every 12 hours
CBC monitoring weekly
Neuropathy risk with prolonged therapy
Fluoroquinolone based regimen
Ciprofloxacin 750 mg PO every 12 hours when susceptible
Levofloxacin 750 mg PO once daily when susceptible
QT and tendon risk counseling
TMP-SMX
1 to 2 double strength tablets PO every 12 hours
Hyperkalemia monitoring
Renal dosing adjustment
Rifampin adjunct for staphylococcal hardware infection
300 to 450 mg PO every 12 hours
Use only with another active agent
Drug interaction screening required
Evidence and guideline levels
Evidence framing
Class I recommendations
Early source control for abscess
Targeted therapy based on bone or deep tissue cultures when available
Class IIa recommendations
MRI for suspected vertebral osteomyelitis with elevated inflammatory markers
IV to oral transition with high bioavailability agents in stable patients
ACEP Level C considerations
In stable patients culture acquisition before antibiotics when feasible
Use of inflammatory markers to support diagnosis and track response
Special Populations
Pregnancy
Pregnancy considerations
Imaging choices
MRI without gadolinium preferred when feasible
CT only when benefit outweighs fetal radiation risk
Antibiotic safety
Avoid tetracyclines
Fetal bone and teeth effects
Alternatives based on susceptibility
Avoid fluoroquinolones when alternatives exist
Cartilage toxicity concern
Use only if benefits outweigh risks
Beta lactams generally acceptable
Cefazolin option for MSSA
Ceftriaxone option for susceptible organisms
Vancomycin acceptable when needed
Therapeutic drug monitoring required
Renal function monitoring
Geriatric
Geriatric considerations
Presentation differences
Fever often absent
Baseline back pain confounding vertebral osteomyelitis
Medication safety
Renal dosing for beta lactams and vancomycin
QT risk with fluoroquinolones
Complication risk
Bacteremia and endovascular source higher likelihood
Functional decline and fall risk from pain and immobility
Pediatrics
Pediatric considerations
Epidemiology and pathogens
Staphylococcus aureus most common
Kingella kingae in young children
Diagnostic approach
Ultrasound for subperiosteal abscess
MRI for early diagnosis and extent
Weight based dosing examples
Cefazolin IV
50 mg per kg per dose IV every 8 hours
Maximum adult dose limits
Clindamycin IV when MRSA risk and susceptible
10 mg per kg per dose IV every 8 hours
C difficile risk counseling for caregivers
Vancomycin IV when MRSA concern
15 mg per kg per dose IV every 6 hours
Therapeutic drug monitoring required
Background
Epidemiology
Epidemiology overview
Common categories
Hematogenous osteomyelitis
Contiguous focus osteomyelitis
Chronic osteomyelitis with sequestrum
High risk groups
Diabetes with foot ulcer
IVDU with bacteremia risk
Post operative and hardware associated infections
Site patterns
Vertebral osteomyelitis common in adults
Metaphyseal long bone involvement common in children
Pathophysiology
Pathophysiology essentials
Inflammation and ischemia
Increased intraosseous pressure
Reduced perfusion and necrosis
Chronic infection features
Sequestrum formation
Involucrum formation
Biofilm pathobiology
Hardware associated infections
Reduced antibiotic penetration and tolerance
Vertebral spread
Disc space involvement in adults
Epidural extension risk
Therapeutic Considerations
Treatment principles
Culture guided therapy priority
Bone culture highest specificity
Blood culture may guide when concordant
Antibiotic penetration and duration
Prolonged therapy required due to avascular necrotic bone
High bioavailability oral therapy acceptable in selected patients
Source control impact
Debridement improves cure rates in chronic osteomyelitis
Abscess drainage reduces bacterial burden
Monitoring strategy
CRP trend for response
Imaging reserved for lack of clinical improvement
Patient Discharge Instructions
Copy discharge instructions
Discharge instructions bundle
Diagnosis explanation
Bone infection concern requiring prolonged therapy
Need for close follow up and lab monitoring
Medications
Antibiotics exactly as prescribed
Do not stop early even if improved
Wound care and activity
Keep wound clean and dry if ulcer present
Offloading device use as instructed
Return immediately for
Fever
Worsening pain
Increasing redness or swelling
New drainage or foul odor
New weakness or numbness
Bowel or bladder changes
Lightheadedness or fainting
Follow up
Infectious diseases appointment timing
Surgical follow up timing
Lab checks schedule for CBC and kidney function
References
Clinical guidelines and consensus
Guideline sources
Infectious Diseases Society of America guidance on native vertebral osteomyelitis
Diagnostic pathway with blood cultures and MRI
Culture directed therapy emphasis
IDSA and IWGDF guidance on diabetic foot infection and osteomyelitis
Severity grading for disposition
Debridement and offloading principles
Surviving Sepsis Campaign recommendations for sepsis and septic shock
Early antibiotics for shock
MAP target 65 mm Hg
Evidence based sources
Evidence sources
Bone biopsy culture as reference standard for pathogen identification
Higher specificity than superficial swab
Improved targeted therapy selection
MRI as preferred imaging for early osteomyelitis and abscess extent
High sensitivity for marrow edema
Specificity limitations with postoperative change and Charcot
High bioavailability oral therapy options for selected stable patients
Criteria based transition strategies
Monitoring for toxicity during prolonged courses
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.